Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 41289 [2014-16453]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 135 / Tuesday, July 15, 2014 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
mstockstill on DSK4VPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Advisory Committee on Breast Cancer
in Young Women (ACBCYW)
The meeting announced below
concerns Evaluating Promising
Strategies to Build the Evidence Base for
Sexual Violence Prevention, Funding
Opportunity Announcement (FOA)
CE14–005, initial review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 11:30 a.m.–12:30
p.m., EDT, July 30, 2014 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Evaluating Promising Strategies to
Build the Evidence Base for Sexual
Violence Prevention, FOA CE14–005.’’
The panel is reconvening to review one
application that was not reviewed in the
previous panel for FOA CE14–005 on
May 15, 2014.
Contact Person For More Information:
Donald Blackman, Ph.D., Scientific
Review Officer, CDC, 4770 Buford
Highway NE., Mailstop F63, Atlanta,
Georgia 30341, Telephone: (770) 488–
0641.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2014–16453 Filed 7–14–14; 8:45 am]
BILLING CODE 4163–18–P
VerDate Mar<15>2010
17:46 Jul 14, 2014
Jkt 232001
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time And Date: 1:00 p.m.–5:00 p.m.,
EST, August 11, 2014.
Place: This meeting is accessible by
teleconference and web access.
Teleconference and web access login
information is as follows:
Toll-Free Telephone: 1–877–917–
7126, Participant passcode: 1594803.
There is also a toll free number for
anyone outside of the USA: TOLL
NUMBER: 1–415–228–4972, Participant
passcode: 1594803.
Net Conference And Web URL:
https://www.mymeetings.com/nc/join/.
Conference number: PW7515819,
Audience passcode: 1594803 and:
https://www.mymeetings.com/nc/
join.php?i=PW7515819&p=1594803
&t=c.
Status: Open to the public, limited
only by the net conference and audio
phone lines available.
Purpose: The committee provides
advice and guidance to the Secretary,
HHS; the Assistant Secretary for Health;
and the Director, CDC, regarding the
formative research, development,
implementation and evaluation of
evidence-based activities designed to
prevent breast cancer (particularly
among those at heightened risk) and
promote the early detection and support
of young women who develop the
disease. The advice provided by the
Committee will assist in ensuring
scientific quality, timeliness, utility, and
dissemination of credible appropriate
messages and resource materials.
Matters For Discussion: The agenda
will include discussions on the current
and emerging topics related to breast
cancer in young women. These include
current survivorship activities and
public health campaign activities. Other
areas of discussion may include risk
communication and health education,
as well as approaches to increase
awareness of clinicians/practitioners
regarding topics such as breast cancer
risk, breast health, symptoms, diagnosis,
and treatment of breast cancer in young
women.
Agenda items are subject to change as
priorities dictate.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
41289
Online Registration Required: All
ACBCYW Meeting participants must
register for the meeting online at least
three business days in advance at
https://www.cdc.gov/cancer/breast/what
_cdc_is_doing/meetings.htm. Please
complete all the required fields before
submitting your registration and submit
no later than August 6, 2014.
Contact Person For More Information:
Temeika L. Fairley, Ph.D., Designated
Federal Officer, National Center for
Chronic Disease Prevention and Health
Promotion, CDC, 4770 Buford Highway,
NE., Mailstop K52, Atlanta, Georgia
30341, Telephone (770) 488–4518, Fax
(770) 488–4760 Email: acbcyw@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention, and Agency for Toxic
Substances and Disease Registry.
Elaine Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2014–16494 Filed 7–14–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–D–0900]
Benefit-Risk Factors To Consider
When Determining Substantial
Equivalence in Premarket Notifications
[510(k)] With Different Technological
Characteristics; Draft Guidance for
Industry and Food and Drug
Administration Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of the draft guidance
document entitled ‘‘Benefit-Risk Factors
to Consider When Determining
Substantial Equivalence in Premarket
Notifications [510(k)] with Different
Technological Characteristics.’’ This
guidance is intended to provide greater
clarity regarding the principal benefitrisk factors that FDA considers during
the review process for a premarket
notification (510(k)) submission when
there are different technological
characteristics between the new device
and the legally marketed (predicate)
SUMMARY:
E:\FR\FM\15JYN1.SGM
15JYN1
]]>Agencies
[Federal Register Volume 79, Number 135 (Tuesday, July 15, 2014)]
[Notices]
[Page 41289]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-16453]
[[Page 41289]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns Evaluating Promising
Strategies to Build the Evidence Base for Sexual Violence Prevention,
Funding Opportunity Announcement (FOA) CE14-005, initial review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting:
Time and Date: 11:30 a.m.-12:30 p.m., EDT, July 30, 2014 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Evaluating Promising Strategies to Build the Evidence Base for
Sexual Violence Prevention, FOA CE14-005.'' The panel is reconvening to
review one application that was not reviewed in the previous panel for
FOA CE14-005 on May 15, 2014.
Contact Person For More Information: Donald Blackman, Ph.D.,
Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F63,
Atlanta, Georgia 30341, Telephone: (770) 488-0641.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2014-16453 Filed 7-14-14; 8:45 am]
BILLING CODE 4163-18-P
